Related Experiment Video
Updated: Apr 7, 2026

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
Published on: September 19, 2019
Bayesian dose escalation in oncology with sharing of information between patient populations
Kristine R Broglio1, Larissa Sandalic2, Tina Albertson2
1Berry Consultants, LLC, 4301 Westbank Drive Suite 140 Bldg B, Austin, TX 78746, United States.
Abstract:
We present a Phase I dose escalation trial design based on a modified continual reassessment method that allows for sharing of information between populations. We describe our approach in the context of a trial for patients with acute lymphoblastic leukemia (ALL) that is currently being conducted. The ALL trial enrolls both adult and pediatric patient populations. Dose escalation and the determination of the maximum tolerated dose (MTD) are performed separately for each population, but to increase efficiency, information about the dose-toxicity curve is shared. Dose escalation rules allow pediatric patients to skip dose levels provided safety has been shown in adults and the dose level is estimated to be safe for pediatric patients. Trial objectives are to efficiently determine the MTD for each population and to minimize the number of pediatric patients required for dose escalation.
Related Concept Videos
Dosage Regimens: Partial Pharmacokinetic Parameters
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Dose-Response Relationship: Overview
Dosage Regimen: Individualization
Analysis of Population Pharmacokinetic Data
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

